In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help patients with type 2 diabetes manage blood sugar.

Research reveals groundbreaking results about Mounjaro and Ozempic in weight loss treatment. Here's what you need to know about these game-changing medications.

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.

Mounjaro, like other GLP-1 drugs, carries potential side effects, including nausea, vomiting, dehydration, and hypoglycaemia – especially when misused or taken alongside other diabetes treatments like insulin. This raises the likelihood of increased A&E admissions, further straining emergency services.

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Drugs like Ozempic, Wegovy and Mounjaro are changing the game for weight loss.  GLP-1 medications were originally intended to treat type 2 diabetes, but a growing number of people are using it for weight loss.